海南日报全媒体记者 孙慧 12月18日上午，一批来自中国香港、符合执行例外措施开展"两头在外"保税维修的货物在海口美兰 国际机场货站申报后，装载货车驶向位于海口国家高新区的海凭国际·海口高新区医疗器械园，随后工 人卸货送入厂房。 第一批符合执行例外措施的保税维修业务落地 在自贸港，维修全球医疗设备 开立生物医疗科技(海口)有限责任公司是深圳开立生物医疗科技股份有限公司(以下简称开立医疗) 全资子公司。开立医疗是国内超声和内窥镜领域的龙头企业，自主研发生产的超声诊断设备、消化呼吸 内窥镜设备等产品远销海内外。随着国际市场份额扩大，海外客户对设备维修的时效性和专业性要求不 断提高。传统海外设备维修需往返国内生产基地，存在耗时久、成本高、影响客户诊疗服务连续性等问 题。 今年7月，商务部印发《海南自由贸易港禁止、限制进出口货物、物品清单》，对部分货物在海南 自贸港"一线"执行例外措施，包括60种取消进口许可证的重点旧机电产品，38种开展"两头在外"的保税 维修货物。该政策自海南自贸港启动全岛封关运作之日起施行。 "我们充分利用海南自贸港可以开展'两头在外'保税维修政策，在海口国家高新区设立全球维修中 心，在海关保税 ...

随着智慧医疗技术在临床领域的广泛应用，医疗设备维护、智能诊疗辅助等岗位人才缺口日益凸显。学 校敏锐捕捉这一行业需求，新增"智能医疗装备技术"专业，组建由医疗设备专家、企业技术骨干与校内 骨干教师构成的教学团队。"课程里既有机械原理、电子电路等基础理论，更有超声诊断设备、监护仪 等实操内容，毕业前就能独立完成常见医疗设备的维护保养。"今年刚毕业的智能医疗装备技术专业毕 业生阚子浩说。 "通过'甘李药业'冠名班的校企联合培养，我不仅掌握了药品生产规范操作，还提前熟悉了企业岗位流 程，毕业时直接通过考核入职，省去了试用期适应环节。"山东医学高等专科学校（以下简称"山东医 专"）2025届药学专业毕业生张玉莹的就业经历，正是该校专业建在产业上，校企合作育人办学实践的 生动写照。 近年来，山东医专紧紧围绕基层医学需求和医药产业发展要求，将产教融合作为人才培养改革的"核心 引擎"，探索形成"专业建在产业上、课程设在岗位上、人才育在实践中"的培养模式，累计为医药健康 产业输送高素质技术技能人才17.6万余名，实现了专业水平与学生就业能力的双重提升，走出了一条具 有医药特色的校企协同育人之路。 专业设置与产业需求同频共振 " ...

Core Viewpoint - The company, KaiLi Medical, is a leading domestic medical device manufacturer focusing on ultrasound diagnostic and endoscopic treatment equipment, with a strong emphasis on independent research and development, production, and sales [1] Financial Performance - For Q3 2025, KaiLi Medical reported a revenue of 1.459 billion yuan, ranking 11th among 42 companies in the industry, while the industry leader, Mindray Medical, achieved 25.834 billion yuan [2] - The net profit for the same period was 33.51 million yuan, placing the company 26th in the industry, with the top performer, Mindray Medical, reporting a net profit of 7.814 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 24.22%, lower than the industry average of 27.21%, indicating good solvency [3] - The gross profit margin was 60.36%, which, despite a decrease from 66.59% in the previous year, remains above the industry average of 48.67% [3] Executive Compensation - The chairman, Chen Zhiqiang, and the general manager, Wu Kunxiang, both received a salary of 900,000 yuan for 2024 and 2023, showing no increase [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 12.75% to 16,100, while the average number of shares held per shareholder decreased by 11.31% to 26,800 [5] - The top ten circulating shareholders included Hong Kong Central Clearing Limited and Huabao CSI Medical ETF, with notable changes in their holdings [5] Market Outlook - According to CICC, the company's performance in the first three quarters of 2025 was below market expectations, with a revenue increase of 4.37% year-on-year, but a significant decline in net profit by 69.25% due to price reductions from centralized procurement and competition [5] - Huatai Securities noted that while revenue has shown rapid growth in Q3 2025, the profit decline was primarily due to increased sales promotion and new product development costs, with expectations for gross margin improvement [6]

Core Viewpoint - The stock price of Kaili Medical reached 35.65 yuan as of August 21, 2025, reflecting a 3.36% increase from the previous trading day [1] Group 1: Company Overview - Kaili Medical specializes in the research, production, and sales of medical devices, including ultrasound diagnostic equipment, endoscopes, and minimally invasive surgical devices [1] - Recently, the company launched several new products in the high-end ultrasound and endoscope sectors, including the high-end full-body machine S80, obstetrics and gynecology machine P80, and the compatibility platform X-2600 [1] Group 2: Financial Performance - For the first half of 2025, the company reported revenue of 964 million yuan, a year-on-year decrease of 4.8% [1] - The net profit attributable to shareholders was 47.03 million yuan, down 72.4% year-on-year [1] - In the second quarter, revenue was 534 million yuan, showing a slight increase of 0.2% year-on-year, but net profit decreased by 44.7% [1] - The company's operating cash flow net amount was -250 million yuan, representing a significant year-on-year decline [1]

Group 1 - The stock price of Kangtai Medical reached 18.34 yuan as of August 15, 2025, reflecting a 1.21% increase from the previous trading day [1] - The opening price for the day was 18.39 yuan, with a high of 18.53 yuan and a low of 18.14 yuan, resulting in a trading volume of 88,800 hands and a transaction amount of 162 million yuan [1] - The company operates in the medical device sector, offering products such as monitors, electrocardiograms, and ultrasound diagnostic equipment, which are widely used in the healthcare industry [1] Group 2 - On August 15, the net outflow of main funds was 3.2962 million yuan, with a cumulative net outflow of 107 million yuan over the past five trading days [1] - The company's segments include medical devices, in vitro diagnostics, and connected healthcare [1]

Group 1 - The trend of Chinese medical device companies "going global" is long-term positive, especially in the upstream supply chain which has formed a certain scale [1] - In Q1 2025, China's medical device export trade total is projected to reach 69.26 billion yuan, a year-on-year increase of 5.03%, with high-end medical devices seeing significant growth [1] - The export value of China's medical device industry is expected to reach 48.75 billion USD in 2024, reflecting a year-on-year growth of 7.3% [1] Group 2 - Over 100 listed medical device companies have already initiated "going global" operations in 2024, covering various product areas such as medical consumables and diagnostic equipment [2] - Companies are advised to consider business, supply chain, and localization strategies for global expansion [2][3] - Localized production and supply chain management are essential for adapting to market demands in different regions [3] Group 3 - Companies like Haier Bio emphasize the importance of localizing product design and marketing to enhance user experience in overseas markets [4] - The trend of "going global" is common among mature, growth, and startup medical device companies, focusing on high-value and high-end products [6] - High-value medical devices, such as deep brain stimulators, require careful economic calculations and long-term service planning before entering foreign markets [6] Group 4 - Companies are encouraged to leverage digitalization and smart technologies to enhance their global strategies, as seen with Mindray Medical's remote monitoring capabilities [7] - Brand building is crucial for domestic medical device companies, with strategies including sponsorship of international sports events to enhance global influence [7] - The medical device market in Europe and the US accounts for over 65% of the global market share, making it a primary target for Chinese companies [8] Group 5 - Key conditions for Chinese medical device companies to "go global" include having sufficient capital, production capacity, and independent R&D capabilities [8] - Collaboration with local hospitals and doctors for joint R&D and clinical trials can facilitate product entry into new markets [8]